




RealRate

PHARMACEUTICAL 2019

MELINTA THERAPEUTICS INC. NEW
Rank 164 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2019

MELINTA THERAPEUTICS INC. NEW Rank 164 of 371

The relative strengths and weaknesses of MELINTA THERAPEUTICS INC. NEW are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MELINTA THERAPEUTICS INC. NEW compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 115% points. The greatest weakness of MELINTA THERAPEUTICS INC. NEW is the variable Assets, Current, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is -124%, being 208% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	149,482
Cost of Goods Sold	41,057
Intangible Assets	229,196
Liabilities, Current	133,606
Liabilities, Non-Current	117,920
Other Assets	61,326
Other Compr. Net Income	0
Other Expenses	25,088
Other Liabilities	0
Other Net Income	1,244
Property and Equipment	1,586
Research and Development	55,409
Revenues	96,430
Selling, General and Administrative Expense	133,312

Output Variable	Value in 1000 USD
Assets	441,590
Liabilities	251,526
Expenses	254,866
Stockholders Equity	190,064
Net Income	-157,192
Comprehensive Net Income	-157,192
Economic Capital Ratio	-124%

